Hypertension and cardiometabolic comorbidity in patients with different levels of blood glucose in the non-diabetic range

Objective. To study the prevalence of hypertension (HTN), concomitant and associated cardiovascular, metabolic diseases and disorders in people with different levels of blood glucose in the non-diabetic range.

Design and methods. A content analysis of 1503 outpatient maps was carried out with the assessment of age, body weight, body mass index (BMI), fasting plasma glucose (FPG), total cholesterol, low density lipoprotein cholesterol (LDL)), overweight/obesity, HTN, atherosclerotic diseases. The changes in carbohydrate metabolism were classified as following: highnormal FPG (5,6-6,0 mmol/l; n = 141; group 1), normoglycemia (FPG up to 5,5 mmol/l; n = 1227; group 2), previously diagnosed prediabetes (n = 54; group 3) and diabetes mellitus (n = 81).

Results. Group 1 was characterized by higher body mass, BMI, FPG, total cholesterol, higher prevalence of dyslipidemia, atherosclerotic diseases, overweight/obesity, HTN (p < 0,001) compared with group 2. The presence of a “highnormal level of FPG” is associated with an increased risk of dyslipidemia (relative risk: RR 1,579; 95 % confidence interval (CI): 1,348-1,803), atherosclerotic diseases (RR2,095; 95 % CI 1,371-3,832), obesity (RR 1,766; 95 % CI 1,568-1,934), AH (RR 1,697; 95 % CI 1,45-1,93). Groups 1 and 3 did not differ by the general characteristics. HTN patients in group 1 compared with group 2 more often had dyslipidemia (p = 0,034) and overweight/obesity (p = 0,014). In patients with HTN, the presence of “highnormal FPG” is associated with an increased risk of dyslipidemia (RR 1,221; 95 % CI 1,005-1,429), overweight/obesity (RR 1,189; 95 % CI 1,0291,319). HTN patients in groups 1 and 3 did not differ in the frequency of dyslipidemia, atherosclerotic diseases, overweight/obesity.

Conclusions. “Highnormal level of FPG” is associated with an increased risk of dyslipidemia, atherosclerotic diseases, HTN, obesity; among HTN patients—with an increased risk of dyslipidemia, overweight/ obesity. Patients with “highnormal FPG” and patients with prediabetes show similar cardiometabolic status.

1. World Health Organization. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. World Health Organization; 2013. Available from: https://apps.who.int/iris/handle/10665/79059

2. Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamono-va GV, Gatagonova TM, Duplyakov DV et al. The prevalence of non-infectious diseases risk factors in Russian population in 20122013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. DEUjj7mi5N67b6LYZPApyoV8Ek 8hdNL1Vy. In Russian.

3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whel-ton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223. doi:10.1016/S0140-6736(05)17741-1

4. Cryer MJ, Horani T, DiPette DJ. Diabetes and hypertension: a comparative review of current guidelines. J Clin Hypertens. 2016;18(2):95-100. doi:10.1111/jch.12638

5. Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61(5):943-947. doi:10.1161/HYPERTENSIONAHA.111.00612

6. Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014;43(1):103-122. doi:10.1016/j.ecl.2013.09.005

7. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57(5):891-897. doi:10.1161/HYPERTENSIONAHA. 110.162446

8. Wilson ML. Prediabetes: beyond the borderline. Nurs Clin North Am. 2017;52(4):665-677. doi:10.1016/j.cnur.2017.07.011

9. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. doi:10.1016/S0140-6736(10)60484-9

10. Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):5-20. doi:10.2337/diacare.26.2007.s5

11. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl.1): S 14-S 31. doi.org/10.2337/dc20-S 002

12. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th Edition M.: UP PRINT, 2019. 2011 р. doi:10.14341/DM221S1. In Russian.

13. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. doi.org/10.1093/eurheartj/ehz455

14. Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am. 2018;47(1):33-50. doi:10.1016/j.ecl.2017.10.001

15. Ratto E, Leoncini G, Viazzi F, Vaccaro V, Parodi A, Falqui V et al. Metabolic syndrome and cardiovascular risk in primary hypertension. JASN. 2006;17(4Suppl2):120-122. doi:10.1681/ASN.2005121328

16. Giordano A, Murano I, Mondini E, Perugini J, Smorlesi A, Severi I. Adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res. 2013;54(9):2423-2436. doi:10.1194/jlr.M038638

17. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88(6):2364-2372. doi:10.1210/jc.2003-030490

18. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727-2729. doi:10.1096/fj.01-0457fje

19. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):82-97. doi:10.1152/ajpcell.00287.2006

20. Meijer RI, De Boer MP, Groen MR, Eringa EC, Rattigan S, Barrett EJ et al. Insulin-induced microvascular recruitment in skin and muscle are related and both are associated with whole-body glucose uptake. Microcirculation. 2012;19(6):494-500. doi:10.1111/j.1549-8719.2012.00174.x

21. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Originally Published. 2006;113:1888-1904. doi:10.1161/CIRCULATIONAHA.105.563213Circulation

22. Lukich E, Matas Z, Boaz M, Shargorodsky M. Increasing derangement of glucose homeostasis is associated with increased arterial stiffness in patients with diabetes, impaired fasting glucose and normal controls. Diabetes Metab Res Rev. 2010;26(5):365-370. doi:10.1002/dmrr.1086

23. Shin JY, Lee HR, Lee DC. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol. 2011 ;10:30. doi:10.1186/1475-2840-10-30

24. Tomiyama H, Hashimoto H, Hirayama Y, Yambe M, Yamada J, Koji Y et al. Synergistic acceleration of arterial stiffening in the presence of raised blood pressure and raised plasma glucose. Hypertension. 2006;47(2):180-188. doi:10.1161/01.HYP.0000198539.34501.1a

25. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med J Br Diabet Assoc. 1992;9(2):114-119. doi:10.1111/j.1464-5491.1992.tb01746.x

26. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107(22):2864-2869. doi:10.1161/01.CIR.0000069826.36125.B4

27. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932-943. doi:10.1161/01.ATV.0000160548.78317.29

28. Madonna R, Balistreri CR, Geng YJ, De Caterina R. Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches. Vascul Pharmacol. 2017;90:1-7. doi:10.1016/j.vph.2017.01.004

29. Strain WD, Paldanius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57. doi:10.1186/s12933-018-0703-2

30. Jung JY, Oh CM, Choi JM, Ryoo JH, Park SK. Longterm risk of hypertension in normoglycemia and prediabetes, and their relation to the change of glycemic state. Am J Hypertens. 2018;31(9):1042-1048. doi:10.1093/ajh/hpy094

31. Schmidt MI, Bracco PA, Yudkin JS, Bensenor IM, Griep RH, Barreto SM et al. Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an occupational cohort study in Brazil. Lancet Diabetes Endocrinol. 2019;7(4):267-277. doi:10.1016/S2213-8587(19)30058-0

32. Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5(1):34-42. doi:10.1016/S2213-8587(16)30321-7

33. Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018; 10(10): CD 012661. doi:10.1002/14651858.CD012661

34. Geva M, Shlomai G, Berkovich A, Maor E, Leibowitz A, Tenenbaum A et al. The association between fasting plasma glucose and glycated hemoglobin in the prediabetes range and future development of hypertension. Cardiovasc Diabetol. 2019;18(1):53. doi:10.1186/s12933-019-0859-4

35. Khosravi A, Gharipour M, Nezafati P, Khosravi Z, Sadeghi M, Khaledifar A et al. Pre-hypertension, pre-diabetes or both: which is best at predicting cardiovascular events in the long term? J Hum Hypertens. 2017;31(6):382-387. doi:10.1038/jhh.2016.42

36. Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5(1):34-42. doi:10.1016/S2213-8587(16)30321-7